文献速递艾滋病与性传播感染结核与非结核分枝杆菌

乌干达TB/HIV合并感染成人中CYP2B6 516 TT基因型者抗结核治疗期间依非韦伦血药浓度升高

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究在166例接受含利福平抗结核治疗的TB/HIV合并感染乌干达成人中,于治疗第2、8、12、24周检测依非韦伦(600 mg每日)血清浓度,并回顾性分析CYP2B6 516G>T多态性。结果显示49.4%患者至少一次浓度>4 mg/L,CYP2B6 516 TT基因型者浓度持续高于4 mg/L且显著高于GG/GT型,提示该基因型是浓度升高的最强预测因素。

要点

  • 近半数TB/HIV合并感染患者抗结核治疗期间依非韦伦血药浓度>4 mg/L。
  • CYP2B6 516 TT基因型者依非韦伦浓度持续>4 mg/L,显著高于GG/GT型。
  • 临床需警惕合抗结核治疗时依非韦伦浓度升高,尽可能个体化给药。

核心结论

  • TB/HIV合并感染乌干达成人中,CYP2B6 516 TT基因型是抗结核治疗期间依非韦伦血药浓度升高的最强预测因素。

研究设计与样本

  • 前瞻性测量166例接受含利福平抗结核治疗及依非韦伦600 mg每日ART的TB/HIV合并感染乌干达成人血清依非韦伦浓度,并于第2、8、12、24周采样。
  • 回顾性采用实时PCR等位基因辨别法检测CYP2B6 516G>T(rs3745274),用单因素和多因素logistic回归分析浓度升高相关因素。

主要发现

  • 166例患者中位年龄34岁(IQR 30-40),男性99例(59.6%),中位CD4计数195 cells/mm3(IQR 71-334),中位BMI 19 kg/m2(IQR 17.6-21.5)。
  • 82例(49.4%)至少一次依非韦伦血清浓度高于参考范围4 mg/L。
  • CYP2B6 516 TT基因型者依非韦伦浓度持续高于4 mg/L,中位9.6 mg/L(IQR 7.3-13.3),显著高于GT型3.4 mg/L(IQR 2.1-5.1)和GG型2.6 mg/L(IQR 1.3-4.0)(Wilcoxon秩和检验P<0.0001)。

关键数值与推荐

  • 依非韦伦血清浓度参考范围上限为4 mg/L;TT基因型中位浓度9.6 mg/L(IQR 7.3-13.3),GT型3.4 mg/L(IQR 2.1-5.1),GG型2.6 mg/L(IQR 1.3-4.0),P<0.0001。

临床怎么用

  • 对TB/HIV合并感染且接受含利福平抗结核治疗的患者,应警惕依非韦伦血药浓度可能升高。
  • 条件允许时对CYP2B6 516 TT基因型或高危患者开展治疗药物监测并实施个体化给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report the efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults on concomitant anti-TB treatment and analyse factors associated with elevated concentrations in this specific population. METHODS: Serum efavirenz concentrations in TB/HIV-coinfected Ugandan adults on efavirenz-based ART (600 mg daily) were measured onsite at 2, 8, 12 and 24 weeks of concomitant anti-TB treatment, including rifampicin. Genetic analysis was done retrospectively through real-time PCR by allelic discrimination (CYP2B6 516G>T, rs3745274). Univariable and multivariable logistic regression analyses were done to assess factors potentially associated with elevated efavirenz serum concentrations. RESULTS: A total of 166 patients were included in the analysis. The median age was 34 (IQR = 30-40) years, 99 (59.6%) were male, the median CD4 cell count was 195 (IQR = 71-334) cells/mm3 and the median BMI was 19 (IQR = 17.6-21.5) kg/m2. Almost half of all patients (82, 49.4%) had at least one efavirenz serum concentration above the reference range of 4 mg/L. The serum efavirenz concentrations of patients with genotype CYP2B6 516 TT were consistently above 4 mg/L and significantly higher than those of patients with GG/GT genotypes: CYP2B6 516 TT 9.6 mg/L (IQR = 7.3-13.3) versus CYP2B6 516 GT 3.4 mg/L (IQR = 2.1-5.1) and CYP2B6 516 GG 2.6 mg/L (IQR = 1.3-4.0) (Wilcoxon rank-sum test: P < 0.0001). CONCLUSIONS: A large proportion of our study participants had at least one efavirenz serum concentration >4 mg/L. The CYP2B6 516 TT genotype was the strongest predictor of high concentration. Physicians should be vigilant that efavirenz serum concentrations may be elevated in patients on concomitant anti-TB treatment and that individualized care is warranted whenever possible.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. von Braun A, Castelnuovo B, Ledergerber B, et al. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. J Antimicrob Chemother. 2019. PMID: 30239753. doi:10.1093/jac/dky379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。